Form 4: NeuroPace Inc. Executive Martha Morrell Reports Acquisition of Common Stock and Stock Options

Chief Medical Officer Martha Morrell reports acquiring 12,500 shares of common stock and 24,950 stock options in NeuroPace Inc.

Summary

• On February 27, 2024, Martha Morrell, Chief Medical Officer of NeuroPace Inc., reported acquiring 12,500 shares of common stock represented by restricted stock units (RSUs) and 24,950 stock options.
• The RSUs vest with 25% on February 27, 2025, and the remaining RSUs vest in twelve equal quarterly installments thereafter.
• The stock options, with an exercise price of $17.11, also vest with 25% on February 27, 2025, and the remaining shares vest in thirty-six equal consecutive monthly installments thereafter.
• Following these transactions, Morrell directly owns 90,262 shares of common stock and 24,950 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive. While insider ownership is generally viewed positively, this is part of a standard compensation package.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge executive sentiment and potential future performance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to increased insider ownership.

Key Dates